JP4392065B2 - 腫瘍および炎症性疾患治療用の新規プロドラッグ - Google Patents

腫瘍および炎症性疾患治療用の新規プロドラッグ Download PDF

Info

Publication number
JP4392065B2
JP4392065B2 JP05598397A JP5598397A JP4392065B2 JP 4392065 B2 JP4392065 B2 JP 4392065B2 JP 05598397 A JP05598397 A JP 05598397A JP 5598397 A JP5598397 A JP 5598397A JP 4392065 B2 JP4392065 B2 JP 4392065B2
Authority
JP
Japan
Prior art keywords
compound
amino
alkyl
glycosyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP05598397A
Other languages
English (en)
Japanese (ja)
Other versions
JPH101495A5 (https=
JPH101495A (ja
Inventor
クラウス・ボスレツト
イエルク・チエツク
マンフレート・ゲルケン
ライナー・シユトラウプ
クロード・モネレ
ジヤン−クロード・フロラン
フレデリツク・シユミツト
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4392065(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JPH101495A publication Critical patent/JPH101495A/ja
Publication of JPH101495A5 publication Critical patent/JPH101495A5/ja
Application granted granted Critical
Publication of JP4392065B2 publication Critical patent/JP4392065B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP05598397A 1996-03-12 1997-03-11 腫瘍および炎症性疾患治療用の新規プロドラッグ Expired - Fee Related JP4392065B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE96103866:8 1996-03-12
EP96103866 1996-03-12

Publications (3)

Publication Number Publication Date
JPH101495A JPH101495A (ja) 1998-01-06
JPH101495A5 JPH101495A5 (https=) 2005-01-20
JP4392065B2 true JP4392065B2 (ja) 2009-12-24

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP05598397A Expired - Fee Related JP4392065B2 (ja) 1996-03-12 1997-03-11 腫瘍および炎症性疾患治療用の新規プロドラッグ

Country Status (24)

Country Link
US (1) US5935995A (https=)
EP (1) EP0795334B1 (https=)
JP (1) JP4392065B2 (https=)
KR (1) KR100466467B1 (https=)
CN (1) CN1168733C (https=)
AT (1) ATE316799T1 (https=)
AU (1) AU708202B2 (https=)
BG (1) BG61900B1 (https=)
BR (1) BRPI9701248B1 (https=)
CA (1) CA2199664C (https=)
CZ (1) CZ297994B6 (https=)
DE (1) DE59712561D1 (https=)
DK (1) DK0795334T3 (https=)
ES (1) ES2257756T3 (https=)
HU (1) HU228764B1 (https=)
NO (1) NO320322B1 (https=)
NZ (1) NZ314368A (https=)
PL (1) PL189604B1 (https=)
RO (1) RO120951B1 (https=)
RU (1) RU2191021C2 (https=)
SG (1) SG50011A1 (https=)
SI (1) SI0795334T1 (https=)
TR (1) TR199700178A2 (https=)
UA (1) UA50719C2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2003018549A2 (en) * 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
EP1541579A1 (en) * 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP1734962A4 (en) * 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN102746336B (zh) * 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
ES2547302T3 (es) * 2007-04-06 2015-10-05 Ziopharm Oncology, Inc. Sales de mostaza de isofosforamida y análogos de las mismas
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
AU2016359234B2 (en) 2015-11-25 2022-09-08 Ligachem Biosciences Inc. Conjugates comprising peptide groups and methods related thereto
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
JP7459063B2 (ja) 2018-05-09 2024-04-01 レゴケム バイオサイエンシズ， インク． 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0538799B1 (en) * 1991-10-25 1995-03-15 TUNGSRAM Részvénytársaság Single-capped low-pressure discharge lamp
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
HU228764B1 (en) 2013-05-28
CN1168733C (zh) 2004-09-29
HU9700579D0 (en) 1997-04-28
AU708202B2 (en) 1999-07-29
CN1163895A (zh) 1997-11-05
SG50011A1 (en) 1998-06-15
NZ314368A (en) 1998-10-28
HUP9700579A2 (en) 1997-12-29
CA2199664A1 (en) 1997-09-12
TR199700178A2 (tr) 1997-09-21
SI0795334T1 (sl) 2006-06-30
BG101290A (en) 1997-09-30
CZ297994B6 (cs) 2007-05-16
CZ74297A3 (en) 1997-09-17
DE59712561D1 (de) 2006-04-13
EP0795334B1 (de) 2006-02-01
MX9701832A (es) 1998-07-31
NO971116D0 (no) 1997-03-11
BG61900B1 (bg) 1998-09-30
BR9701248A (pt) 1999-10-13
ATE316799T1 (de) 2006-02-15
BR9701248A8 (pt) 2013-06-18
RU2191021C2 (ru) 2002-10-20
EP0795334A2 (de) 1997-09-17
UA50719C2 (uk) 2002-11-15
CA2199664C (en) 2008-05-20
PL189604B1 (pl) 2005-08-31
US5935995A (en) 1999-08-10
NO320322B1 (no) 2005-11-21
EP0795334A3 (de) 1997-09-24
JPH101495A (ja) 1998-01-06
ES2257756T3 (es) 2006-08-01
HUP9700579A3 (en) 1999-05-28
KR100466467B1 (ko) 2005-06-29
AU1620597A (en) 1997-09-18
DK0795334T3 (da) 2006-06-06
PL318878A1 (en) 1997-09-15
BRPI9701248B1 (pt) 2022-01-18
NO971116L (no) 1997-09-15
RO120951B1 (ro) 2006-10-30
KR970065550A (ko) 1997-10-13

Similar Documents

Publication Publication Date Title
JP4392065B2 (ja) 腫瘍および炎症性疾患治療用の新規プロドラッグ
JP3841311B2 (ja) プロドラッグ、その製造および医薬としての使用
AU740694B2 (en) Preparation having increased in vivo tolerability
ES3029483T3 (en) Folate receptor binding conjugates of antifolates
HK1211493A1 (en) Conjugates for treating diseases caused by psma expressing cells
EP0647450A1 (en) Improved prodrugs for enzyme mediated activation
CN104520309A (zh) 抗真菌抗生素两性霉素b的n-取代第二代衍生物及其制备方法和应用
BR112021004689A2 (pt) conjugados glp-1 liberáveis
CN120957753A (zh) 生物活性结合物、其制备方法和其用途
CN102803228A (zh) 酸不稳定触发子单元
EP0953357A1 (en) Nephrotropic drugs
WO2004093821A2 (en) Treatment of anthrax infection using inhibitors of lethal factor protease activity
MXPA97001832A (en) New profarmacos for inflamator tumors and disease therapy
CN105899234A (zh) Dupa-茚并异喹啉缀合物
Carter¹ et al. Current Investigational Drugs of Interest in the Chemotherapy Program of the
EA041296B1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090915

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091009

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121016

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131016

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees